Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study
Marcus Mall, Rossa Brugha, Silvia Gärtner, et al.
American Journal of Respiratory and Critical Care Medicine (2022) Vol. 206, Iss. 11, pp. 1361-1369
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Cystic Fibrosis
Thida Ong, Bonnie W. Ramsey
JAMA (2023) Vol. 329, Iss. 21, pp. 1859-1859
Closed Access | Times Cited: 136
Cystic Fibrosis
Hartmut Grasemann, Félix Ratjen
New England Journal of Medicine (2023) Vol. 389, Iss. 18, pp. 1693-1707
Closed Access | Times Cited: 130
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis
Laura Schaupp, Annalisa Addante, Mirjam Völler, et al.
European Respiratory Journal (2023) Vol. 62, Iss. 2, pp. 2202153-2202153
Closed Access | Times Cited: 106
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
Jennifer L. Goralski, Jordana E. Hoppe, Marcus Mall, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 208, Iss. 1, pp. 59-67
Open Access | Times Cited: 73
The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches
Simon Y. Graeber, Marcus Mall
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1185-1198
Closed Access | Times Cited: 68
CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis
Jennifer L. Taylor‐Cousar, Paul D. Robinson, Michal Shteinberg, et al.
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1171-1184
Closed Access | Times Cited: 64
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
Mafalda Bacalhau, Mariana Camargo, Grace Anne Vieira Magalhães Ghiotto, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 410-410
Open Access | Times Cited: 61
Cystic fibrosis
Marcus Mall, Pierre–Régis Burgel, Carlo Castellani, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 27
Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians
Vito Terlizzi, Philip M. Farrell
Current problems in pediatric and adolescent health care (2024) Vol. 54, Iss. 6, pp. 101637-101637
Closed Access | Times Cited: 24
Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis
Jennifer Loske, Mirjam Völler, Soeren Lukassen, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 209, Iss. 11, pp. 1338-1350
Open Access | Times Cited: 20
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
Jordana E. Hoppe, Ajay S. Kasi, Jessica E. Pittman, et al.
The Lancet Respiratory Medicine (2025)
Open Access | Times Cited: 10
Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis
Vito Terlizzi, Cristina Fevola, Martina Cecchetti, et al.
Journal of Cystic Fibrosis (2025)
Closed Access | Times Cited: 2
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
Vito Terlizzi, Miquéias Lopes‐Pacheco
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access | Times Cited: 2
Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation
Ido Sadras, Eitan Kerem, Galit Livnat, et al.
Journal of Cystic Fibrosis (2023) Vol. 22, Iss. 6, pp. 1062-1069
Closed Access | Times Cited: 40
Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
Nikoletta Kapouni, Maria Moustaki, Konstantinos Douros, et al.
Children (2023) Vol. 10, Iss. 3, pp. 554-554
Open Access | Times Cited: 36
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial
Claire Wainwright, Susanna A. McColley, Paul McNally, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 208, Iss. 1, pp. 68-78
Open Access | Times Cited: 35
Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers
Christina J. Bathgate, Emily F. Muther, Anna M. Georgiopoulos, et al.
Pediatric Pulmonology (2023) Vol. 58, Iss. 9, pp. 2469-2477
Closed Access | Times Cited: 29
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events
Bonnie W. Ramsey, Christoph U. Correll, David R. DeMaso, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 209, Iss. 3, pp. 299-306
Open Access | Times Cited: 29
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
Nicole Mayer-Hamblett, John P. Clancy, Raksha Jain, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 10, pp. 932-944
Open Access | Times Cited: 23
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles
Mirjam Stahl, Martha Dohna, Simon Y. Graeber, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 3, pp. 2400004-2400004
Open Access | Times Cited: 15
Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)
Alan Shi, H. Nguyen, Chiaoyun Benson Kuo, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 3, pp. 566-572
Closed Access | Times Cited: 11
The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
Pierre–Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 11, pp. 888-900
Closed Access | Times Cited: 10
Intestinal current measurement detects age-dependent differences in CFTR function in rectal epithelium
Simon Y. Graeber, Olaf Sommerburg, Yin Yu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system
Chengyu Zhu, Zhiwei Cui, Tingting Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis
Simon Y. Graeber, Anita Balázs, Niklas Ziegahn, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12365-12365
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top